Ablation to Reduce Atrial Fibrillation Burden and Improve Outcomes: JACC Review Topic of the Week

Overview

Journal J Am Coll Cardiol

Specialty Cardiology & Vascular Diseases

Date 2023 Aug 30

PMID 37648353

Authors

Hannah T Schwennesen

Jason G Andrade

Kathryn A Wood

Jonathan P Piccini

Affiliations

Soon will be listed here.

Abstract

Atrial fibrillation is the most common atrial arrhythmia and accounts for a significant burden of cardiovascular disease globally. With advances in implanted and wearable cardiac monitoring technology, it is now possible to readily and accurately quantify an individual's time spent in atrial fibrillation. This review summarizes the relationship between atrial fibrillation burden and adverse cardiovascular and cerebrovascular outcomes and discusses the role of catheter ablation to mitigate the morbidity and mortality associated with greater burden of atrial fibrillation.

Citing Articles

Catheter Ablation in Atrial Fibrillation: Recent Advances.

Singh S, Garg L, Kanjwal M, Bliden K, Tantry U, Gurbel P J Clin Med. 2025; 13(24.

PMID: 39768622 PMC: 11679530. DOI: 10.3390/jcm13247700.

Machine Learning-Based Identification of High-Risk Patterns in Atrial Fibrillation Ablation Outcomes.

Oloko-Oba M, Liu Y, Wood K, Lloyd M, Ho J, Hertzberg V medRxiv. 2024; .

PMID: 39649597 PMC: 11623726. DOI: 10.1101/2024.11.27.24318097.

Associations of lipids and lipid-modifying drug target genes with atrial fibrillation risk based on genomic data.

Tao Y, Wang Y, Yin Y, Zhang K, Gong Y, Ying H Lipids Health Dis. 2024; 23(1):175.

PMID: 38851763 PMC: 11161942. DOI: 10.1186/s12944-024-02163-4.

Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference.

Linz D, Andrade J, Arbelo E, Boriani G, Breithardt G, Camm A Europace. 2024; 26(4).

PMID: 38591838 PMC: 11003300. DOI: 10.1093/europace/euae070.

Selected Advances in the Anti-arrhythmic Management of Atrial Fibrillation: 2023.

Reiffel J J Innov Card Rhythm Manag. 2024; 15(1):5728-5734.

PMID: 38304092 PMC: 10829416. DOI: 10.19102/icrm.2024.15014.

References

Friedman D, Field M, Rahman M, Goldstein L, Sha Q, Sidharth M . Catheter ablation and healthcare utilization and cost among patients with paroxysmal versus persistent atrial fibrillation. Heart Rhythm O2. 2021; 2(1):28-36. PMC: 8183841. DOI: 10.1016/j.hroo.2020.12.017. View

Wong J, Conen D, Van Gelder I, McIntyre W, Crijns H, Wang J . Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure. J Am Coll Cardiol. 2018; 71(23):2603-2611. DOI: 10.1016/j.jacc.2018.03.519. View

Steinberg B, Hellkamp A, Lokhnygina Y, Patel M, Breithardt G, Hankey G . Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J. 2014; 36(5):288-96. PMC: 4313363. DOI: 10.1093/eurheartj/ehu359. View

Thomas K, Al-Khalidi H, Silverstein A, Monahan K, Bahnson T, Poole J . Ablation Versus Drug Therapy for Atrial Fibrillation in Racial and Ethnic Minorities. J Am Coll Cardiol. 2021; 78(2):126-138. PMC: 8354144. DOI: 10.1016/j.jacc.2021.04.092. View

Hunter R, Berriman T, Diab I, Kamdar R, Richmond L, Baker V . A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol. 2014; 7(1):31-8. DOI: 10.1161/CIRCEP.113.000806. View

Santhanakrishnan R, Wang N, Larson M, Magnani J, McManus D, Lubitz S . Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction. Circulation. 2016; 133(5):484-92. PMC: 4738087. DOI: 10.1161/CIRCULATIONAHA.115.018614. View

Al-Khatib S, Thomas L, Wallentin L, Lopes R, Gersh B, Garcia D . Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J. 2013; 34(31):2464-71. DOI: 10.1093/eurheartj/eht135. View

Andrade J, Macle L, Verma A, Deyell M, Champagne J, Dubuc M . Quality of Life and Health Care Utilization in the CIRCA-DOSE Study. JACC Clin Electrophysiol. 2020; 6(8):935-944. DOI: 10.1016/j.jacep.2020.04.017. View

Taillandier S, Brunet Bernard A, Lallemand B, Simeon E, Pericart L, Clementy N . Prognosis in patients hospitalized with permanent and nonpermanent atrial fibrillation in heart failure. Am J Cardiol. 2014; 113(7):1189-95. DOI: 10.1016/j.amjcard.2013.12.024. View

10.

Proietti R, Birnie D, Ziegler P, Wells G, Verma A . Postablation Atrial Fibrillation Burden and Patient Activity Level: Insights From the DISCERN AF Study. J Am Heart Assoc. 2018; 7(23):e010256. PMC: 6405544. DOI: 10.1161/JAHA.118.010256. View

11.

Deng H, Shantsila A, Guo P, Potpara T, Zhan X, Fang X . Sex-related risks of recurrence of atrial fibrillation after ablation: Insights from the Guangzhou Atrial Fibrillation Ablation Registry. Arch Cardiovasc Dis. 2019; 112(3):171-179. DOI: 10.1016/j.acvd.2018.10.006. View

12.

Vanassche T, Lauw M, Eikelboom J, Healey J, Hart R, Alings M . Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J. 2014; 36(5):281-7a. DOI: 10.1093/eurheartj/ehu307. View

13.

Go A, Reynolds K, Yang J, Gupta N, Lenane J, Sung S . Association of Burden of Atrial Fibrillation With Risk of Ischemic Stroke in Adults With Paroxysmal Atrial Fibrillation: The KP-RHYTHM Study. JAMA Cardiol. 2018; 3(7):601-608. PMC: 6145663. DOI: 10.1001/jamacardio.2018.1176. View

14.

Corley S, Epstein A, DiMarco J, Domanski M, Geller N, Greene H . Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004; 109(12):1509-13. DOI: 10.1161/01.CIR.0000121736.16643.11. View

15.

January C, Samuel Wann L, Calkins H, Chen L, Cigarroa J, Cleveland Jr J . 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the.... J Am Coll Cardiol. 2019; 74(1):104-132. DOI: 10.1016/j.jacc.2019.01.011. View

16.

Chew D, Li Z, Steinberg B, OBrien E, Pritchard J, Bunch T . Arrhythmic Burden and the Risk of Cardiovascular Outcomes in Patients With Paroxysmal Atrial Fibrillation and Cardiac Implanted Electronic Devices. Circ Arrhythm Electrophysiol. 2022; 15(2):e010304. DOI: 10.1161/CIRCEP.121.010304. View

17.

Calkins H, Reynolds M, Spector P, Sondhi M, Xu Y, Martin A . Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol. 2009; 2(4):349-61. DOI: 10.1161/CIRCEP.108.824789. View

18.

Piccini J, Passman R, Turakhia M, Connolly A, Nabutovsky Y, Varma N . Atrial fibrillation burden, progression, and the risk of death: a case-crossover analysis in patients with cardiac implantable electronic devices. Europace. 2018; 21(3):404-413. DOI: 10.1093/europace/euy222. View

19.

Parkash R, Wells G, Rouleau J, Talajic M, Essebag V, Skanes A . Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial. Circulation. 2022; 145(23):1693-1704. DOI: 10.1161/CIRCULATIONAHA.121.057095. View

20.

Kuniss M, Pavlovic N, Velagic V, Hermida J, Healey S, Arena G . Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. Europace. 2021; 23(7):1033-1041. PMC: 8286851. DOI: 10.1093/europace/euab029. View